2026 ASH®
Annual Meeting & Exposition December 12-15, 2026 ▪ New Orleans, Louisiana

Paper Details

Abstracts, authors, affiliations, and disclosures.

Monday, December 14, 2026
10:30 a.m. - 12:00 p.m.
MCCNO - La Nouvelle C
Efficacy of T cell engagers and anti-CD38 therpies in real world studies
Access, Representation, Population Health, Treatment Considerations, Combination Therapy, Therapy Sequence, Biological Therapies, Bispecific Antibody Therapy, Immunotherapy, Non-Biological Therapies, Chemotherapy, Biological Processes, Immune Mechanism, Clinical Practice (Health Services and Quality), Diseases, Lymphoid Malignancies, Plasma Cell Disorders, Research, Clinical Research, Epidemiology, Real-World Evidence, Study Population, Human, Adult
PAPER

845 Real-world outcomes after bispecific antibody discontinuation for ongoing response in relapsed/refractory multiple myeloma: A US myeloma immunotherapy consortium analysis

Andrew Jay Portuguese, MD, Saurabh Zanwar, MBBS, MD2, Asya Varshavsky, MD3, Matias Eugenio Sanchez, MD4, Ariel Grajales-Cruz, MD5, Omar Alexis Castaneda Puglianini, MD6, Doris K. Hansen, MD7, Kenneth H. Shain, MD, PhD8, Jack Khouri, MD9, Mikhaila Rice, PharmD10, Shahzad Raza, MD11, Faiz Anwer, MD12, Meera Mohan, MD, MS13, Mackenzie Maberry, MD14, Bruno Almeida Costa, MD15, Hector Jose Garcia Pleitez, MD16, Poy Theprungsirikul, MD17, Shonali Midha, MD18, Omar Nadeem, MD19, Danai Dima, MD20, Christy Khouderchah, PharmD, BCOP21, Guizhen Chen22, Rahul Banerjee, MD23, Masooma Shifa Rana, MBBS24, Surbhi Sidana, MD25, Melinda Tan, MD26, Christoph Schaefers, MD27, Yi Lin Jr, MD, PhD28, Aimaz Afrough, MD29, Larry D Anderson Jr, MD, PhD30, Anthony Dominick31, Kelley Julian, PharmD, BCOP32, Doug W. Sborov, MD, MS33, Francesca Cottini, MD34, Timothy O'Brien, MD35, Murali Janakiram, MBBS36, Darren Pan, MD37, Christopher J. Ferreri, MD38, Binoy Yohannan, MD39, Veronika Bachanova, MD, PhD40, Noa Biran, MD41, Chenyu Lin, MD42, Karen Sweiss, PharmD43, Megan M Herr, PhD44, Anita Nguyen45, Margaret Minett, N/A46, Nisha Joseph, MD47, James A Davis, PharmD, BCOP48, Hira Mian, MD49, Natalie S Callander, MD50
1 Fred Hutchinson Cancer Center, Seattle, Washington, United States
2 Mayo Clinic, Rochester, Minnesota, United States
3 Fox Chase Cancer Center, Philadelphia, Pennsylvania, United States
4 University of Illinois, Chicago, Illinois, United States
5 H. Lee Moffitt Cancer Center and Research Institute, Tampa, Florida, United States
6 H. Lee Moffitt Cancer Center and Research Institute, Tampa, Florida, United States
7 H. Lee Moffitt Cancer Center and Research Institute, Tampa, Florida, United States
8 H. Lee Moffitt Cancer Center and Research Institute, Tampa, Florida, United States
9 Cleveland Clinic, Cleveland, Ohio, United States
10 Cleveland Clinic, Cleveland, Ohio, United States
11 Cleveland Clinic, Cleveland, Ohio, United States
12 Cleveland Clinic, Cleveland, Ohio, United States
13 MD Anderson Cancer Center, Houston, Texas, United States
14 MD Anderson Cancer Center, Houston, Texas, United States
15 MD Anderson Cancer Center, Houston, Texas, United States
16 MD Anderson Cancer Center, Houston, Texas, United States
17 Dana-Farber Cancer Institute, Boston, Massachusetts, United States
18 Dana-Farber Cancer Institute, Boston, Massachusetts, United States
19 Dana-Farber Cancer Institute, Boston, Massachusetts, United States
20 Fred Hutchinson Cancer Center, Seattle, Washington, United States
21 Fred Hutchinson Cancer Center, Seattle, Washington, United States
22 University of Washington, Seattle, Washington, United States
23 Fred Hutchinson Cancer Center, Seattle, Washington, United States
24 Stanford University, Stanford, California, United States
25 Stanford University, Stanford, California, United States
26 Mayo Clinic, Rochester, Minnesota, United States
27 Mayo Clinic, Rochester, Minnesota, United States
28 Mayo Clinic, Rochester, Minnesota, United States
29 UT Southwestern Medical Center, Dallas, Texas, United States
30 UT Southwestern Medical Center, Dallas, Texas, United States
31 Medical University of South Carolina, Charleston, South Carolina, United States
32 Huntsman Cancer Institute, Salt Lake City, Utah, United States
33 Huntsman Cancer Institute, Salt Lake City, Utah, United States
34 The Ohio State University, Columbus, Ohio, United States
35 UH Seidman Cancer Center, Cleveland, Ohio, United States
36 City of Hope, Duarte, California, United States
37 University of California San Francisco, San Francisco, California, United States
38 Levine Cancer Institute, Charlotte, North Carolina, United States
39 University of Minnesota, Minneapolis, Minnesota, United States
40 University of Minnesota, Minneapolis, Minnesota, United States
41 Hackensack Meridian Health, Hackensack, New Jersey, United States
42 Duke University, Durham, North Carolina, United States
43 University of Illinois, Chicago, Illinois, United States
44 Roswell Park, Buffalo, New York, United States
45 Washington University, St. Louis, Missouri, United States
46 Washington University, St. Louis, Missouri, United States
47 Winship Cancer Institute, Atlanta, Georgia, United States
48 Medical University of South Carolina, Charleston, South Carolina, United States
49 McMaster University, Hamilton, Ontario, Canada
50 University of Wisconsin, Madison, Wisconsin, United States

Background: BCMA- and GPRC5D-directed bispecific antibodies (BsAbs) produce deep responses in relapsed/refractory multiple myeloma (RRMM), but pivotal studies generally treated until progression or intolerance. Prolonged therapy may increase infection risk, cost, and T-cell exhaustion, creating interest in response-adapted discontinuation. Despite early data from small series and clinical trials, real-world outcomes after discontinuation for ongoing response remain incompletely defined.

Methods: We performed a 21-site US Myeloma Immunotherapy Consortium retrospective study of patients (pts) with RRMM treated with commercial BsAbs. We included only the index BCMA-directed BsAb course and excluded BsAb use for bridging therapy. The primary exposure was investigator-classified permanent discontinuation for ongoing response, defined as elective permanent treatment cessation in patients with ongoing response without disease progression or unacceptable toxicity. This was modeled as a time-dependent variable: patients contributed reference-state time until discontinuation, then switched to the ongoing-response discontinuation state. The reference state included ongoing treatment and permanent discontinuation for progression, toxicity, death, or other reasons. Patients without post-discontinuation progression/death required ≥30 days of follow-up. Stabilized inverse probability of treatment weighting (IPTW) balanced ECOG 0-1 vs ≥2, prior lines, ≥1 high-risk cytogenetic abnormality, and response depth. Primary endpoints were progression-free survival (PFS) and overall survival (OS) from BsAb initiation; non-relapse mortality (NRM) was analyzed as a secondary endpoint. IPTW-weighted time-dependent Cox models estimated PFS, OS, and NRM associations; recurrent infections were analyzed with an IPTW-weighted quasi-Poisson rate model using the same time-dependent exposure. Sensitivity analyses varied IPTW covariates and cohort definitions, including an available-data IMS/IMWG 2025 Consensus Genomic Staging (CGS) approximation.

Results: We included 1,832 eligible BsAb-treated pts. The primary IPTW complete-case cohort included 939 pts, of whom 43 discontinued for ongoing response: 24 teclistamab (55.8%), 10 talquetamab (23.3%), and 9 elranatamab (20.9%). Median time on BsAb before discontinuation was 6.1 months (IQR, 3.3-13.3). For PFS, 918 pts were evaluable with 462 progression/death events; for OS, 937 were evaluable with 284 deaths. All 43 ongoing-response discontinuers entered the time-dependent discontinuation state; after entry, 6 PFS events and 5 deaths occurred.

Median post-discontinuation follow-up was 10.2 months. Treatment-free PFS was 92.8%, 85.4%, and 76.8% at 6, 12, and 18 months, respectively; median treatment-free PFS was not reached. In the primary Cox model, ongoing-response discontinuation was associated with lower progression/death hazard vs the reference state (PFS HR 0.21, 95% CI 0.08-0.53; p<0.001) and lower death hazard (OS HR 0.35, 95% CI 0.13-0.94; p=0.037). NRM was not significantly different (HR 0.39, 95% CI 0.11-1.42; p=0.153). Infection rates were lower after ongoing-response discontinuation (rate ratio 0.46, 95% CI 0.21-0.98; p=0.045). Model-based PFS estimates for stopped vs reference were 75.3% vs 60.1% at 12 months and 69.5% vs 41.1% at 24 months; corresponding OS estimates were 88.0% vs 81.6% and 80.7% vs 63.6%. Findings were consistent across sensitivity analyses varying IPTW covariates and cohort definitions, including adjustment for triple-class refractory status, baseline LDH, baseline hemoglobin, baseline ferritin, and CGS approximation; restriction to ≥VGPR; exclusion of discontinuation within ≤60 days; exclusion of true extramedullary disease; and exclusion of talquetamab (PFS HR range, 0.15-0.37; OS HR range, 0.22-0.67).

Conclusions: In this multicenter real-world analysis, BsAb discontinuation for ongoing response was associated with favorable PFS and OS outcomes after IPTW adjustment and time-dependent exposure modeling. These findings suggest selected responders may maintain disease control off therapy, although the number of ongoing-response discontinuers was limited and favorable disease biology, deep treatment sensitivity, and residual confounding may contribute. Together with emerging finite-duration BsAb data, these results support prospective response-adapted discontinuation studies with standardized response assessment, longitudinal monitoring, and planned retreatment strategies.

Andrew Jay Portuguese, MD: Pfizer - Research Funding; Regeneron - Research Funding; Karyopharm - Consultancy (Includes expert testimony)